
The federal government is set to introduce a new long‑acting HIV prevention injection, Lenacapavir, in eight states and the Federal Capital Territory (FCT). Health officials said the drug, which is given twice a year, is for people who are HIV‑negative but at high risk of infection. About 52,000 doses have been secured for the first phase, and the rollout will start in selected facilities so authorities can closely monitor safety and effectiveness.
Officials said Lenacapavir offers an alternative to daily oral PrEP for people who find it hard to take tablets every day. The rollout is part of Nigeria’s National Pre‑Exposure Prophylaxis Implementation Plan (2025–2028) and will complement existing prevention methods rather than replace them. Early reports show only mild side effects, such as pain at the injection site, and the drug is not a treatment for people living with HIV nor does it protect against other sexually transmitted infections or pregnancy.
The programme will be guided by data and stakeholder collaboration, with a focus on service delivery, supply chain management and community engagement. Health leaders stressed that the injection is an extra layer of protection for high‑risk groups and urged continued use of other prevention tools. International partners and civil society groups welcomed the move, calling it a potentially important step to reduce new infections and accelerate progress toward ending AIDS as a public health threat by 2030.

